Sign in to view content

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Caroline Baumal, MD, FASRS

Video
Published 2021

Related

New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2022
Progression of diabetic retinopathy in patients treated with 0.2 μg/day
Raymond Iezzi, MD, MS
Updates from the Field
2017
Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive nAMD: TENAYA/LUCERNE Post Hoc Analyses
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2025

Category: Diabetic Retinopathy

See more